Regenerative medicine holds significant promise for addressing diseases and irreversible damage that are challenging to treat with conventional methods, making it a prominent research focus in modern medicine. Research on stem cells, a key area within regenerative medicine due to their self-renewal capabilities, is expanding, positioning them as a novel therapeutic option. Stem cells, utilized in various treatments, are categorized based on their differentiation potential and the source tissue. The term ‘stem cell’ encompasses a broad spectrum of cells, which can be derived from embryonic tissues, adult tissues, or generated by reprogramming differentiated cells. These cells, applied across numerous medical disciplines including cardiovascular, neurological, and hematological disorders, as well as wound healing, demonstrate varying therapeutic applications based on their differentiation capacities, each presenting unique advantages and limitations. Nevertheless, the existing literature lacks a comprehensive synthesis examining stem cell therapy and its cellular subtypes across different medical specialties. This review addresses this lacuna by collectively categorizing contemporary stem cell research according to medical specialty and stem cell classification, offering an exhaustive analysis of their respective benefits and constraints, thereby elucidating multifaceted perspectives on the clinical implementation of this therapeutic modality.
Despite therapeutic advancements, malignant melanoma remains a leading cause of skin cancer-related mortality, with incidence continuing to rise globally. Traditional prognostic tools offer important clinical guidance but fail to capture the biological heterogeneity of melanoma or reliably predict responses to emerging therapies. In this review, we summarize recent advances in prognostic and predictive molecular biomarkers reported over the past five years. We discuss immunohistochemical and tissue-based markers, circulating biomarkers, microRNAs, and gene expression profiles that enhance risk stratification and inform surveillance strategies. We also review immune-related markers that may predict response to immune-checkpoint inhibitor therapy. Lastly, we highlight investigational biomarkers—including gene signatures, epigenomic alterations, and microbiome influences—that are shaping the future landscape. Together, these advances reflect a shift toward precision oncology in melanoma, with the integration of biomarker-driven strategies offering the potential to personalize treatment and improve patient outcomes.
Mycosis fungoides, the most common primary cutaneous T-cell lymphoma, presents notable diagnostic challenges. In its early stages, it may resemble inflammatory dermatoses both clinically and histologically, causing delays in diagnosis. These factors can lead to treatment delays, allowing the disease to progress and adversely affecting the patient’s quality of life. To address this issue, the use of skin imaging techniques like dermoscopy, reflectance confocal microscopy, optical coherence tomography, and high-frequency ultrasound has increased in recent years. These techniques assist in diagnosis and treatment monitoring, reducing unnecessary biopsies by guiding accurate sampling from the most relevant sites and improving staging accuracy. This review provides a thorough overview of non-invasive skin imaging methods employed in the diagnosis and management of mycosis fungoides.